Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 4, 2016, Pages 710-716

  Williams, Kirsten M ^a,b   Cheng, Guang Shing ^c   Pusic, Iskra ^d   Jagasia, Madan ^e   Burns, Linda ^f   Ho, Vincent T ^g   Pidala, Joseph ^h   Palmer, Jeanne ⁱ   Johnston, Laura ^j   Mayer, Sebastian ^k   Chien, Jason W ^l   Jacobsohn, David A ^a   Pavletic, Steven Z ^b   Martin, Paul J ^c   Storer, Barry E ^c   Inamoto, Yoshihiro ^m   Chai, Xiaoyu ^c   Flowers, Mary E D ^c   Lee, Stephanie J ^c  

^a CHILDREN S RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c USA   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ MAYO CLINIC   (United States)

^j STANFORD UNIVERSITY   (United States)

^k WEILL CORNELL MEDICAL COLLEGE   (United States)

^l Gilead Sciences   (United States)

^m NATIONAL CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

Azithromycin; Bronchiolitis obliterans syndrome; Fluticasone; Hematopoietic cell transplantation; Leukotrienes; Lung chronic graft versus host disease; Montelukast

Indexed keywords

AZITHROMYCIN; FLUTICASONE; MONTELUKAST; PREDNISONE; ACETIC ACID DERIVATIVE; ANTIINFLAMMATORY AGENT; QUINOLINE DERIVATIVE;

ARTICLE; BEDTIME DOSAGE; BRONCHIOLITIS OBLITERANS; BRONCHITIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COUGHING; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEVER; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; LUNG INFECTION; MULTICENTER STUDY; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PNEUMOTHORAX; RESPIRATORY TRACT DISEASE; SEPSIS; SHORT FORM 36; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; WELLBEING; ADULT; ADVERSE EFFECTS; AGED; ALLOTRANSPLANTATION; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECTS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; LUNG; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; QUALITY OF LIFE; SURVIVAL ANALYSIS;

ACETATES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; AZITHROMYCIN; BRONCHIOLITIS OBLITERANS; DISEASE PROGRESSION; FLUTICASONE; FORCED EXPIRATORY VOLUME; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LUNG; MALE; MIDDLE AGED; QUALITY OF LIFE; QUINOLINES; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84960473094     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.10.009     Document Type: Article

References (50)

1. Williams K.M., Chien J.W., Gladwin M.T., Pavletic S.Z. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009, 302:306-314.
2. Palmer J., Williams K., Inamoto Y., et al. Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2014, 20:337-344.
3. Sengsayadeth S.M., Srivastava S., Jagasia M., Savani B.N. Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:1479-1487.
4. Chien J.W., Duncan S., Williams K.M., Pavletic S.Z. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010, 16(1 Suppl):S106-114.
5. Au B.K., Au M.A., Chien J.W. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:1072-1078.
6. Bergeron A., Godet C., Chevret S., et al. Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis. Bone Marrow Transplant 2013, 48:819-824.
7. Thompson P.A., Lim A., Panek-Hudson Y., et al. Screening with spirometry is a useful predictor of later development of noninfectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2014, 20:781-786.
8. Husain A.N., Siddiqui M.T., Holmes E.W., et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999, 159:829-833.
9. Nicod L.P. Mechanisms of airway obliteration after lung transplantation. Proc Am Thorac Soc 2006, 3:444-449.
10. Girnita A.L., Duquesnoy R., Yousem S.A., et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 2005, 5:131-138.
11. Panoskaltsis-Mortari A., Tram K.V., Price A.P., et al. A new murine model for bronchiolitis obliterans post-bone marrow transplant. Am J Respir Crit Care Med 2007, 176:713-723.
12. Srinivasan M., Flynn R., Price A., et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood 2012, 119:1570-1580.
13. Clark J.G., Crawford S.W., Madtes D.K., Sullivan K.M. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. Ann Intern Med 1989, 111:368-376.
14. Dudek A.Z., Mahaseth H., DeFor T.E., Weisdorf D.J. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003, 9:657-666.
15. Nishio N., Yagasaki H., Takahashi Y., et al. Late-onset non-infectious pulmonary complications following allogeneic hematopoietic stem cell transplantation in children. Bone Marrow Transplant 2009, 44:303-308.
16. Lucid C.E., Savani B.N., Engelhardt B.G., et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. Bone Marrow Transplant 2011, 46:426-429.
17. Hildebrandt G.C., Fazekas T., Lawitschka A., et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant 2011, 46:1283-1295.
18. Jagasia M.H., Greinix H.T., Arora M., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2015, 201:389-401.
19. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
20. Yanik G.A., Horowitz M.M., Weisdorf D.J., et al. Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol. Biol Blood Marrow Transplant 2014, 20:858-864.
21. Lam D.C., Lam B., Wong M.K., et al. Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT-a randomized double-blinded placebo-controlled study. Bone Marrow Transplant 2011, 46:1551-1556.
22. Bergeron A., Chevret S., Chagnon K., et al. Budesonide/formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2015, 191:1242-1249.
23. Williams K.M., Pavletic S.Z., Lee S.J., et al. Interim analysis of a phase II trial of montelukast for the treatment of bronchiolitis obliterans syndrome after HSCT reveal immunobiology of disease. Biol Blood Marrow Transplant 2013, 19:S109-S392.
24. Norman B.C., Jacobsohn D.A., Williams K.M., et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant 2011, 46:1369-1373.
25. Khalid M., Al Saghir A., Saleemi S., et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J 2005, 25:490-493.
26. Bashoura L., Gupta S., Jain A., et al. Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 41:63-67.
27. Gerhardt S.G., McDyer J.F., Girgis R.E., et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003, 168:121-125.
28. Gottlieb J., Szangolies J., Koehnlein T., et al. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008, 85:36-41.
29. Yates B., Murphy D.M., Forrest I.A., et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005, 172:772-775.
30. Medoff B.D., Seung E., Wain J.C., et al. BLT1-mediated T cell trafficking is critical for rejection and obliterative bronchiolitis after lung transplantation. J Exp Med 2005, 202:97-110.
31. Wilborn J., Bailie M., Coffey M., et al. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 1996, 97:1827-1836.
32. Or R., Gesundheit B., Resnick I., et al. Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study. Transplantation 2007, 83:577-581.
33. Bergeron A., Belle A., Chevret S., et al. Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2007, 39:547-553.
34. Whitford H., Orsida B., Kotsimbos T., et al. Bronchoalveolar lavage cellular profiles in lung transplantation: the effect of inhaled corticosteroids. Ann Transplant 2000, 5:31-37.
35. Whitford H., Walters E.H., Levvey B., et al. Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation: a double-blind, placebo-controlled trial. Transplantation 2002, 73:1793-1799.
36. Maimon N., Lipton J.H., Chan C.K., Marras T.K. Macrolides in the treatment of bronchiolitis obliterans in allograft recipients. Bone Marrow Transplant 2009, 44:69-73.
37. Crapo R.O., Morris A.H., Gardner R.M. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981, 123:659-664.
38. Yanik G.A., Mineishi S., Levine J.E., et al. Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:1044-1054.
39. Wang M.L., Petsonk E.L. Repeated measures of FEV1 over six to twelve months: what change is abnormal?. J Occup Environ Med 2004, 46:591-595.
40. Lee S.J., Wolff D., Kitko C., et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant 2015, 21:984-999.
41. Lee S.J., Kim H.T., Ho V.T., et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant 2006, 38:305-310.
42. Lee S., Cook E.F., Soiffer R., Antin J.H. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2002, 8:444-452.
43. Philit F., Wiesendanger T., Archimbaud E., et al. Post-transplant obstructive lung disease ("bronchiolitis obliterans"): a clinical comparative study of bone marrow and lung transplant patients. Eur Respir J 1995, 8:551-558.
44. Sanchez J., Torres A., Serrano J., et al. Long-term follow-up of immunosuppressive treatment for obstructive airways disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997, 20:403-408.
45. Chien J.W., Martin P.J., Gooley T.A., et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003, 168:208-214.
46. Holland H.K., Wingard J.R., Beschorner W.E., et al. Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG. Blood 1988, 72:621-627.
47. Duell T., van Lint M.T., Ljungman P., et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med 1997, 126:184-192.
48. Curtis D.J., Smale A., Thien F., et al. Chronic airflow obstruction in long-term survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant 1995, 16:169-173.
49. Marras T.K., Chan C.K., Lipton J.H., et al. Long-term pulmonary function abnormalities and survival after allogeneic marrow transplantation. Bone Marrow Transplant 2004, 33:509-517.
50. Pavletic S.Z., Martin P., Lee S.J., et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006, 12:252-266.